CN1259902C - 制造紫杉醇和白蛋白的纳米颗粒的方法 - Google Patents
制造紫杉醇和白蛋白的纳米颗粒的方法 Download PDFInfo
- Publication number
- CN1259902C CN1259902C CNB031083617A CN03108361A CN1259902C CN 1259902 C CN1259902 C CN 1259902C CN B031083617 A CNB031083617 A CN B031083617A CN 03108361 A CN03108361 A CN 03108361A CN 1259902 C CN1259902 C CN 1259902C
- Authority
- CN
- China
- Prior art keywords
- paclitaxel
- acid
- albumin
- aseptic
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229930012538 Paclitaxel Natural products 0.000 title claims abstract description 56
- 229960001592 paclitaxel Drugs 0.000 title claims abstract description 56
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 title claims abstract description 25
- 102000009027 Albumins Human genes 0.000 title claims abstract description 20
- 108010088751 Albumins Proteins 0.000 title claims abstract description 20
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 35
- 239000000843 powder Substances 0.000 claims abstract description 28
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000007864 aqueous solution Substances 0.000 claims abstract description 22
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 33
- 239000000243 solution Substances 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000007908 nanoemulsion Substances 0.000 claims description 14
- 230000008014 freezing Effects 0.000 claims description 12
- 238000007710 freezing Methods 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 abstract description 4
- 238000000265 homogenisation Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 32
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000001954 sterilising effect Effects 0.000 description 9
- 238000004659 sterilization and disinfection Methods 0.000 description 9
- 238000007738 vacuum evaporation Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000004531 microgranule Substances 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000000079 presaturation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Epoxy Compounds (AREA)
Abstract
一种制备有抗肿瘤性质的紫杉醇和白蛋白的纳米颗粒的方法，用此方法，将通过向白蛋白与氯仿的水溶液中加入粉末状紫杉醇得到的混合物进行高压均质处理。
Description
技术领域
本发明涉及制备紫杉醇和白蛋白的纳米颗粒的方法，能用于获得抗肿瘤组合物。
背景技术
紫杉醇是在文献中已知的天然物质，具有重要的抗肿瘤活性：它的弱水溶性使其难于对人给药，由于此原因，已开发了多种能使其可注射的系统。
根据这些系统中的一个，紫杉醇与生物相容性且有很强的与紫杉醇结合能力的人血清白蛋白(HSA)联合，并通过已知的超声波、高压匀质化和微流化技术形成可注射乳剂(Allemann等，Eur.J.Pharm.Biopharm.39(5)，173-191(1993))。
基于这些要素，并通过使用上述超声波、高压匀化技术，美国VivoRx药物公司已开发了含有紫杉醇和HSA的制剂CAPXOL(R)。
在US 5439686、US 5498421、US 5560933和相应的WO94/18954中，VivoRx要求保护用超声波技术制备的紫杉醇和HSA的微粒，得到平均粒径(MPS)＜10微米的颗粒。在这些专利中记载的制备方法不能用于工业化规模，并且如此得到的微粒有太高的MPS，这使其不适于和不能用于对病人给药。
VivoRx很清楚这一点，因此它在US 5916596和US 6096331及WO 98/14174和WO 99/00113中记载并要求保护通过用无菌0.9％NaCl水溶液重制紫杉醇和HSA的冷冻干燥粉末而得到的无菌纳米乳剂，其MPS＜0.2微米。如引证的专利所述的，这些用高压匀化方法得到的纳米乳剂据称有高的稳定性，此处术语“稳定性”的意义既表示MPS不随时间改变，也表示不出现纳米颗粒沉淀(US 6096331，实施例11)。
按前述VivoRx专利的教导(见US 5916596的实施例1、5和6)，先分别制备紫杉醇的溶液和含有HSA的水溶液，然后将这些相混合在一起，并在室温(0℃和+44℃之间)将这样得到的混合物在9000至40000psi之间的高压下进行匀质化处理。
蒸发除去溶剂并通过无菌滤器(0.22微米)过滤后，将混合物在-20℃和-80℃之间冷冻，并最终在+20℃和+35℃之间的温度下加热冻干，产生具有抗肿瘤性质的能用于制备可注射制剂的粉末。
必须如此制备两个分离的相(一个含有紫杉醇，另一个含有HSA)，然后在其高压匀质化之前混合在一起。这需要使用至少两个分别的反应器和用相应的混合制备两个分别的溶液，所有都要在无菌条件下完成，包括高的设施成本、完成混合操作的时间很长，并需要溶剂的旋转蒸发(在匀质化处理结束时)，随后通过无菌滤器过滤，结果总产率较低。
发明内容
因此本发明的主要目的是提供一种制备紫杉醇和HSA的纳米颗粒的无菌冷冻干燥粉末的方法，它需要使用单一反应器形成将进行匀质化处理的含有紫杉醇和HSA的液体混合物，并可以在非常短的时间内，以低于现有技术的成本完成。
通过下面的方法达到了这一目的和进一步的目的，在该方法中，将温度为0℃至40℃之间的含有紫杉醇和白蛋白的水性混合物，在9000至40000psi之间的高压下经过匀质化处理，产生纳米乳剂，它在-20℃和-80℃之间冷冻，并最终在+20℃和+35℃之间的温度下加热冻干，其中所述的水性混合物是在无菌条件下通过将所述白蛋白溶解在无菌水中达到2％-3％(W/V)浓度，然后向此白蛋白溶液中加入2％-4％(V/V)的氯仿，然后加入占溶液中白蛋白重量5.4％-20.0％的无菌粉末状的紫杉醇而得到的。加入液体混合物中的无菌粉末状紫杉醇的量优选为白蛋白重量的5.6％至19.4％之间。
重要的是注意到：在此方法中使用无菌粉末状的紫杉醇不仅大大简化了流程本身，并且此方法与现有技术相比，还使在匀化处理前完成各种组分的混合所需的时间大大缩短，而也能得到更好的最终产率，并简化了为得到所需的无菌冷冻干燥粉末所遵循的条件。
通过按前述方式操作，得到了用紫杉醇和HSA的纳米颗粒的混合物形成的粉末，它完全类似或等同于用前述在先申请记载的用更复杂、费力和昂贵的方法能得到的粉末。
从这些混合物，当使用在US 5916596推荐的压力范围内的Avestin匀质器加工时，得到pH＝6.7的纳米乳剂，当它在如所述专利所报道的旋转蒸发器中蒸发时，产生MPS约为0.2微米(在蒸发后MPS的增加＞0.02微米)的纳米乳剂，它在其可注射的生理溶液的制剂中不稳定(MPS的增加约为0.05微米，在约12小时内倾向于沉积)，并难于过滤通过0.22微米滤器进行灭菌，这些滤器易于阻塞并使紫杉醇的产率降低到非常低的值(降至或低于30％)。
当按US 5916596和US 6096331报道的冷冻干燥并重制后，用如上所述的本发明的方法和按在先专利的方法制备的产品的稳定性(按US 6096331实施例11的教导评价)是能接受的，但从未超过24小时。
已令人惊奇地发现，如果在含有HS A的液体混合物中加入至少一种其量足以使粉末状纳米颗粒的重制可注射水性混合物的pH达到5.4和5.8之间(优选使pH达到5.5和5.7之间)的生物相容性酸(在向其中加入粉末状的紫杉醇之前)，可注射形态的冷冻干燥并重制混合物的稳定性大大增加，超过24小时。
加入上述酸或类似物质形成了本发明的一部分。
优选地，所述酸选自盐酸、柠檬酸、磷酸、醋酸、生物相容性有机或无机酸，但柠檬酸是最优选的一种。
具体实施方式
为阐明本发明的特征，现在描述它的一些非限定性的实施例，一些用生理pH的液体混合物，一些用酸酸化以突出使用酸所产生的差异。
实施例1
制备pH6.7的制剂
以无菌软化水将符合FDA规范的可注射的209％(w/v)HSA水溶液(pH＝6.9±0.5)稀释到3％(w/v)。
在高能振荡下将41.4ml所述溶液与1.25ml无菌氯仿，并与73.6mg(溶液中白蛋白重量的5.9％)粉末状无菌紫杉醇(效价＞99％)混合，然后将混合物在高压匀化器内(适当地灭菌)处理直至得到纳米乳剂(MPS约0.2微米)，将其真空蒸发以除去溶剂，在无菌条件下冷冻并冻干48小时。
得到的含有4.60％(W/W)紫杉醇的粉末，与0.9％NaCl水溶液重制形成紫杉醇浓度为2mg/ml的溶液。得到的制剂具有0.486微米的MPS，pH＝6.7，稳定性＜12小时。
得到的产品与用US 5916596实施例1的方法制备的产品有同样的特性。
实施例2
制备pH6.7的制剂
以无菌软化水将符合FDA规范的可注射的25％(w/v)HSA水溶液(pH＝6.9±0.5)稀释到2％(w/v)。
将49.0ml所述溶液与1.0ml无菌氯仿，并与72.5mg(白蛋白重量的7.4％)粉末状无菌紫杉醇(效价＞99％)混合，然后将混合物在高压匀化器内(适当地灭菌)处理直至得到纳米乳剂(MPS约0.2微米)，将其真空蒸发以除去溶剂，通过无菌滤器过滤(0.2微米)，在无菌条件下冷冻并冻干48小时。
得到的含有0.60％(W/W)紫杉醇的粉末，与0.9％NaCl水溶液重制形成紫杉醇浓度为2mg/ml的溶液。得到的制剂具有0.25微米的MPS，pH＝6.7，稳定性＜12小时。
实施例3
制备pH6.7的制剂
以无菌软化水将符合FDA规范的可注射的20％(w/v)HSA水溶液(pH＝6.9±0.5)稀释到3％(w/v)。
将46.7ml所述溶液与1.40ml无菌氯仿，并与108.5mg(白蛋白的7.7％)粉末状无菌紫杉醇(效价＞99％)混合，然后将混合物在高压匀化器内(适当地灭菌)处理直至得到纳米乳剂(MPS约0.2微米)，将其真空蒸发以除去溶剂，通过无菌滤器过滤(0.2微米)，在无菌条件下冷冻并冻干48小时。
得到的含有0.77％(W/W)紫杉醇的粉末，与0.9％NaCl水溶液重制形成紫杉醇浓度为2mg/ml的溶液。得到的制剂具有0.12微米的MPS，pH＝6.7，稳定性＜12小时。
如已在说明书的开始部分说明的，过滤导致紫杉醇相当大的损失(冷冻干燥粉末含有0.55％紫杉醇而非实施例2的5.2％)。这使将得到的制剂的MPS＜0.2微米。
实施例4
制备pH6.7的制剂
以无菌软化水将符合FDA规范的可注射的25％(w/v)HSA水溶液(pH＝6.9±0.5)稀释到3％(w/v)。
将29.1ml所述溶液与0.90ml无菌氯仿，并与67.0mg(白蛋白的7.7％)粉末状无菌紫杉醇(效价＞99％)混合，然后将混合物在高压匀化器内(适当地灭菌)处理直至得到纳米乳剂(MPS约0.2微米)，将其真空蒸发以除去溶剂，通过无菌滤器过滤(0.2微米)，在无菌条件下冷冻并冻干48小时。
得到含有0.70％(W/W)紫杉醇的粉末再与0.9％NaCl水溶液重制形成紫杉醇浓度为1.5mg/ml的溶液。得到的制剂具有0.25微米的MPS，pH＝6.7，稳定性＜12小时。
得到的产品与用US 5916596实施例5的方法制备的产品有同样的特性。
实施例5
制备pH6.7的制剂
以无菌软化水将符合FDA规范的可注射的20％(w/v)HSA水溶液(pH＝6.9±0.5)稀释到2.5％(w/v)，并用氯仿预饱和(1％V/V)。
将48.5ml所述溶液与1.0ml无菌氯仿，并与75mg(白蛋白的6.2％)粉末状无菌紫杉醇(效价＞99％)混合，然后将混合物在高压匀化器内(适当地灭菌)处理直至得到纳米乳剂(MPS约0.2微米)，将其真空蒸发以除去溶剂，通过无菌滤器过滤(0.2微米)，在无菌条件下冷冻并冻干48小时。
得到含有0.70％(W/W)紫杉醇的粉末，再与0.9％NaCl水溶液重制形成紫杉醇浓度为2.2mg/ml的溶液。得到的制剂具有0.18微米的MPS，pH＝6.7，稳定性＜12小时。
在实施例3结束时进行的观察在此情况下也得到验证。
实施例6
制备pH＝5.6的制剂
以无菌软化水将FDA规范的可注射的25％(w/v)HSA水溶液(pH＝6.9±0.5)稀释到3％(w/v)，用1MHCl将pH调节到5.6，HCl与白蛋白中的一些碱性基团成盐。
将57ml预先灭菌的所述溶液在强力搅拌下与1.40ml无菌氯仿，并与108mg(白蛋白重量的6.3％)粉末状无菌紫杉醇(效价＞99％)混合至少30分钟。
将混合物在匀化器内(适当地灭菌)在高压(9000-40000psi)下处理直至得到纳米乳剂(MPS＜0.2微米)，在无菌条件下将其快速冷冻到-80℃并冻干55小时，同时升温至+30℃。
将得到含有4.83％(W/W)紫杉醇和4％(w/w)水的粉末，与0.9％NaCl水溶液重制形成紫杉醇浓度为2mg/ml的溶液。得到的制剂具有0.175微米的MPS，pH＝5.6，稳定性＞24小时。
用磷酸代替盐酸得到相同的结果。
实施例7
制备pH＝5.4的制剂
以无菌软化水将符合FDA规范的可注射的25％(w/v)HSA水溶液稀释到3％(w/v)，用柠檬酸将pH调节到5.4，柠檬酸与白蛋白中的一些碱性基团成盐。
将50ml预先灭菌的所述溶液在强力搅拌下与1.23ml无菌氯仿，并与98mg(白蛋白的6.5％)粉末状无菌紫杉醇(效价＞99％)混合至少40分钟。
将混合物在匀化器内(适当地灭菌)在高压(9000-40000psi)下处理直至得到纳米乳剂(MPS＜0.2微米)，在无菌条件下将其快速冷冻到-30℃并冻干57小时，同时升温至+35℃。
将得到的含有4.80％(W/W)紫杉醇和3.8％(w/w)水的粉末，与0.9％NaCl水溶液重制形成紫杉醇浓度为2mg/ml的溶液。得到的制剂具有0.19微米的MPS，pH＝5.4，稳定性＞24小时。
用醋酸代替柠檬酸得到相同的结果。
实施例8
制备pH＝5.5的制剂
以无菌软化水将FDA规范的可注射的25％(w/v)HSA水溶液稀释到3％(w/v)，用无菌柠檬酸将pH调节到5.5，柠檬酸与白蛋白中的一些碱性基团成盐。
将37ml所述溶液在强力搅拌下与0.91ml无菌氯仿，并与71mg(白蛋白的6.4％)粉末状无菌紫杉醇(效价＞99％)混合至少40分钟，然后将混合物冷却到5-8℃。
将混合物在匀化器内(适当地灭菌)在高压(9000-40000psi)下处理直至得到纳米乳剂(MPS＜0.2微米)，在无菌条件下将其快速冷冻到-80℃并冻干58小时，同时升温至+30℃。
将得到的含有4.70％(W/W)紫杉醇和4.5％(w/w)水的粉末，与0.9％NaCl水溶液重制形成紫杉醇浓度为2mg/ml的溶液。得到的制剂具有0.185微米的MPS，pH＝5.5，稳定性＞24小时。
实施例9
制备pH＝5.5的制剂
以无菌软化水将符合FDA规范的可注射的20％(w/v)HSA水溶液(pH＝6.9±0.5)稀释到3％(w/v)，用柠檬酸将pH调节到5.5，柠檬酸与白蛋白中的一些碱性基团成盐。
将110ml所述溶液与4.10ml无菌氯仿，并与639mg(白蛋白的19.4％)粉末状无菌紫杉醇(效价＞99％)混合，然后将混合物在高压匀化器内(适当地灭菌)处理直至得到纳米乳剂(MPS约0.2微米)，将其通过无菌滤器过滤(0.2微米)，真空蒸发以除去溶剂，在无菌条件下冷冻并冻干48小时。
将得到的含有10.8％(W/W)紫杉醇的粉末，与0.9％NaCl水溶液重制形成紫杉醇浓度为2mg/ml的溶液。得到的制剂具有0.15微米的MPS，稳定性＞24小时。
Claims (7)
1.一种制备由紫杉醇和人血清白蛋白的纳米颗粒构成的无菌冷冻干燥粉末的方法，该方法包括将含有紫杉醇和白蛋白的水性混合物在0℃-40℃之间的温度，9000至40000psi之间的高压下经过均质化处理，得到纳米乳剂，它在-20℃至-80℃之间的温度下冷冻，最后经过加热到+20℃至35℃之间的温度而冻干，该方法的特征在于所述水性混合物是这样获得的：在无菌条件下，通过将2％至3％(W/V)所述白蛋白溶解在无菌水中，然后向所述白蛋白溶液中加入2％至4％(V/V)的无菌氯仿，再加入占溶液中白蛋白重量5.4％至20.0％(W/W)的无菌粉末状的紫杉醇。
2.根据权利要求1所述的方法，其特征在于加入所述白蛋白溶液中的无菌粉末状的紫杉醇的量在白蛋白重量的5.6％至19.4％(W/W)之间。
3.根据权利要求1或2所述的方法，其特征在于在加入紫杉醇之前，向所述白蛋白溶液中加入至少一种生物相容性酸，其量足以使粉末状纳米颗粒重制形成的水性可注射混合物的pH达到5.4-5.8之间。
4.根据权利要求3所述的方法，其特征在于所述酸的量是使所述重制形成的水溶液的pH达到5.5至5.7之间的量。
5.根据权利要求3或4所述的方法，其特征在于所述的酸选自生物相容性有机酸和无机酸。
6.根据权利要求5所述的方法，其特征在于所述的酸是盐酸、柠檬酸、磷酸或醋酸。
7.根据权利要求6所述的方法，其特征在于所述的酸是柠檬酸。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2002MI000681A ITMI20020681A1 (it) | 2002-03-29 | 2002-03-29 | Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina |
| ITMI2002A000681 | 2002-03-29 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006100770064A Division CN1911446A (zh) | 2002-03-29 | 2003-03-28 | 制备紫杉醇和白蛋白的纳米颗粒的方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1448128A CN1448128A (zh) | 2003-10-15 |
| CN1259902C true CN1259902C (zh) | 2006-06-21 |
Family
ID=11449619
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006100770064A Pending CN1911446A (zh) | 2002-03-29 | 2003-03-28 | 制备紫杉醇和白蛋白的纳米颗粒的方法 |
| CNB031083617A Expired - Lifetime CN1259902C (zh) | 2002-03-29 | 2003-03-28 | 制造紫杉醇和白蛋白的纳米颗粒的方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006100770064A Pending CN1911446A (zh) | 2002-03-29 | 2003-03-28 | 制备紫杉醇和白蛋白的纳米颗粒的方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20030185894A1 (zh) |
| EP (1) | EP1348431A1 (zh) |
| JP (2) | JP4794115B2 (zh) |
| KR (1) | KR20030078722A (zh) |
| CN (2) | CN1911446A (zh) |
| AU (1) | AU2003200920A1 (zh) |
| BR (1) | BR0300846A (zh) |
| CA (1) | CA2423915A1 (zh) |
| IL (1) | IL154762A0 (zh) |
| IT (1) | ITMI20020681A1 (zh) |
| MX (1) | MXPA03002543A (zh) |
| NO (1) | NO334407B1 (zh) |
| NZ (1) | NZ524605A (zh) |
| RU (1) | RU2003108821A (zh) |
| ZA (1) | ZA200302040B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109793728A (zh) * | 2013-01-11 | 2019-05-24 | 阿布拉科斯生物科学有限公司 | 治疗胰腺癌的方法 |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070117863A1 (en) * | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030133955A1 (en) * | 1993-02-22 | 2003-07-17 | American Bioscience, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US8137684B2 (en) | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US8853260B2 (en) * | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| KR100789008B1 (ko) * | 1997-06-27 | 2007-12-26 | 아브락시스 바이오사이언스 인크. | 신규 약물 제제 |
| KR20200083657A (ko) | 2002-12-09 | 2020-07-08 | 아브락시스 바이오사이언스, 엘엘씨 | 약리학적 물질의 조성물 및 그 전달방법 |
| CA3054535A1 (en) | 2005-02-18 | 2006-08-24 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8735394B2 (en) * | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| CN101287507B (zh) * | 2005-08-12 | 2012-12-05 | 刘江 | 用于淋巴靶向的方法和装置 |
| KR101643416B1 (ko) | 2005-08-31 | 2016-07-27 | 아브락시스 바이오사이언스, 엘엘씨 | 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조방법 |
| PL3311805T3 (pl) | 2005-08-31 | 2020-07-27 | Abraxis Bioscience, Llc | Kompozycje zawierające słabo rozpuszczalne w wodzie środki farmaceutyczne i środki przeciwdrobnoustrojowe |
| AR054215A1 (es) * | 2006-01-20 | 2007-06-13 | Eriochem Sa | Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit |
| EP1870649A1 (en) | 2006-06-20 | 2007-12-26 | Octapharma AG | Lyophilisation targetting defined residual moisture by limited desorption energy levels |
| US20080280987A1 (en) * | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| KR20100095587A (ko) * | 2007-12-13 | 2010-08-31 | 노파르티스 아게 | 유기 화합물 |
| AU2009234127B2 (en) * | 2008-04-10 | 2015-04-30 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| EP2156823A1 (en) * | 2008-08-14 | 2010-02-24 | Pharmatex Italia Srl | Process for the preparation of sterile powdered pharmeceutical compounds in the form of micro and nanoparticles |
| CN101658516B (zh) * | 2008-08-26 | 2011-10-05 | 齐鲁制药有限公司 | 紫杉醇类药物组合物及其制备方法 |
| PL2419732T3 (pl) | 2009-04-15 | 2020-05-18 | Abraxis Bioscience, Llc | Kompozycje nanocząstek wolnych od prionów i sposoby ich wytwarzania |
| WO2011017835A1 (en) * | 2009-08-11 | 2011-02-17 | Nanjing University | Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding |
| CA2785926A1 (en) * | 2009-12-31 | 2011-07-07 | Mannkind Corporation | Injectable formulations for parenteral administration |
| EP2898884B1 (en) | 2010-03-26 | 2018-05-09 | Abraxis BioScience, LLC | Methods of treatment of hepatocellular carcinoma |
| MX2012011155A (es) | 2010-03-29 | 2012-12-05 | Abraxis Bioscience Llc | Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos. |
| EP2552415B1 (en) | 2010-03-29 | 2016-09-07 | Abraxis BioScience, LLC | Methods of treating cancer |
| KR100971087B1 (ko) * | 2010-05-06 | 2010-07-16 | 김현수 | 불투명부에 암막기능을 갖는 블라인드지의 제직방법 |
| NZ706745A (en) | 2010-06-04 | 2017-01-27 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
| CN102274190B (zh) * | 2010-06-11 | 2012-12-05 | 上海现代药物制剂工程研究中心有限公司 | 一种注射用紫杉醇白蛋白亚微粒及其制备方法 |
| CN102078306A (zh) * | 2011-01-11 | 2011-06-01 | 无锡圆容生物医药股份有限公司 | 一种含有重组人血白蛋白的紫杉醇纳米颗粒冷冻干燥制剂 |
| PL2790675T3 (pl) | 2011-12-14 | 2019-12-31 | Abraxis Bioscience, Llc | Zastosowanie polimerowych rozczynników do liofilizacji lub zamrażania cząstek |
| AU2013233094A1 (en) | 2012-03-16 | 2014-10-23 | Taiho Pharmaceutical Co., Ltd. | Novel antitumor agent comprising combination of three agents |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| ES2804323T3 (es) | 2013-03-12 | 2021-02-05 | Abraxis Bioscience Llc | Procedimientos de tratamiento de cáncer de pulmón |
| MX2015011753A (es) | 2013-03-14 | 2015-12-07 | Abraxis Bioscience Llc | Metodos para tratar cancer de vegija. |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| WO2017004249A1 (en) | 2015-06-29 | 2017-01-05 | Abraxis Bioscience, Llc | Methods of treating epithelioid cell tumors |
| CN105012251A (zh) * | 2015-08-24 | 2015-11-04 | 吉林大学 | 注射用紫杉烷类药物白蛋白纳米粒冻干制剂及制备方法 |
| WO2018048958A1 (en) * | 2016-09-06 | 2018-03-15 | Mayo Foundation For Medical Education And Research | Paclitaxel-albumin-binding agent compositions and methods for using and making the same |
| CN109789226B (zh) * | 2016-09-27 | 2021-11-26 | 艾姆戈特株式会社 | 利用携带抗癌剂的人血清白蛋白纳米粒子的肝动脉化疗栓塞术用组合物及其制造方法 |
| CN110062622B (zh) * | 2016-10-27 | 2022-10-14 | 珠海贝海生物技术有限公司 | 多西他赛和人血清白蛋白的中性pH组合物 |
| BR112020018910A2 (pt) | 2018-03-20 | 2020-12-29 | Abraxis Bioscience, Llc | Métodos de tratamento de transtorno do sistema nervoso central através da administração de nanopartículas de um unibidor de mtor e de uma albumina |
| CN108524452A (zh) * | 2018-05-08 | 2018-09-14 | 辽宁大学 | 一种紫杉醇白蛋白纳米粒的制备方法和应用 |
| CN110496111B (zh) * | 2018-05-18 | 2021-07-23 | 国家纳米科学中心 | 一种白蛋白纳米复合结构及其制备方法和应用 |
| KR20220106758A (ko) | 2019-10-28 | 2022-07-29 | 아브락시스 바이오사이언스, 엘엘씨 | 알부민 및 라파마이신의 제약 조성물 |
| CN110585444A (zh) * | 2019-10-31 | 2019-12-20 | 董军 | 一种中西医结合药物及其制备方法与应用 |
| CN114681408B (zh) * | 2020-12-26 | 2023-06-23 | 四川汇宇制药股份有限公司 | 白蛋白结合型紫杉醇纳米粒的制备方法 |
| KR102526793B1 (ko) * | 2021-11-03 | 2023-04-28 | 주식회사 에스엔바이오사이언스 | 입도분포 유지 안정성이 개선된 알부민 결합 탁산 나노입자 제조방법 |
| GB202401848D0 (en) | 2024-02-11 | 2024-03-27 | Univ College Dublin Nat Univ Ireland Dublin | Albumin nanoparticles |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US5362478A (en) * | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
| EP0693924B2 (en) * | 1993-02-22 | 2008-04-09 | Abraxis BioScience, Inc. | Methods for (in vivo) delivery of biologics and compositions useful therefor |
| US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| ATE317703T1 (de) * | 1997-06-12 | 2006-03-15 | Innovata Plc | Polymer-wirkstoff-konjugate zur behandlung von krebs |
| KR100789008B1 (ko) * | 1997-06-27 | 2007-12-26 | 아브락시스 바이오사이언스 인크. | 신규 약물 제제 |
| AU5241199A (en) * | 1998-07-30 | 2000-02-21 | Novopharm Biotech Inc. | Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin |
| US20020041898A1 (en) * | 2000-01-05 | 2002-04-11 | Unger Evan C. | Novel targeted delivery systems for bioactive agents |
| IL152180A0 (en) * | 2000-04-10 | 2003-05-29 | Teva Pharma | Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents |
| ITMI20001107A1 (it) * | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
-
2002
- 2002-03-29 IT IT2002MI000681A patent/ITMI20020681A1/it unknown
-
2003
- 2003-03-03 EP EP03004629A patent/EP1348431A1/en not_active Withdrawn
- 2003-03-05 IL IL15476203A patent/IL154762A0/xx unknown
- 2003-03-05 AU AU2003200920A patent/AU2003200920A1/en not_active Abandoned
- 2003-03-07 NZ NZ524605A patent/NZ524605A/en not_active IP Right Cessation
- 2003-03-10 US US10/383,639 patent/US20030185894A1/en not_active Abandoned
- 2003-03-13 ZA ZA200302040A patent/ZA200302040B/xx unknown
- 2003-03-14 JP JP2003070028A patent/JP4794115B2/ja not_active Expired - Lifetime
- 2003-03-24 MX MXPA03002543A patent/MXPA03002543A/es unknown
- 2003-03-26 BR BR0300846-0A patent/BR0300846A/pt not_active Application Discontinuation
- 2003-03-27 KR KR10-2003-0019242A patent/KR20030078722A/ko not_active Application Discontinuation
- 2003-03-28 CN CNA2006100770064A patent/CN1911446A/zh active Pending
- 2003-03-28 CA CA002423915A patent/CA2423915A1/en not_active Abandoned
- 2003-03-28 RU RU2003108821/15A patent/RU2003108821A/ru not_active Application Discontinuation
- 2003-03-28 NO NO20031448A patent/NO334407B1/no not_active IP Right Cessation
- 2003-03-28 CN CNB031083617A patent/CN1259902C/zh not_active Expired - Lifetime
-
2006
- 2006-01-17 US US11/334,004 patent/US20060121119A1/en not_active Abandoned
-
2011
- 2011-03-01 JP JP2011043799A patent/JP2011132253A/ja not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109793728A (zh) * | 2013-01-11 | 2019-05-24 | 阿布拉科斯生物科学有限公司 | 治疗胰腺癌的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1911446A (zh) | 2007-02-14 |
| KR20030078722A (ko) | 2003-10-08 |
| CA2423915A1 (en) | 2003-09-29 |
| NZ524605A (en) | 2004-03-26 |
| JP2011132253A (ja) | 2011-07-07 |
| RU2003108821A (ru) | 2004-11-10 |
| MXPA03002543A (es) | 2005-08-26 |
| EP1348431A1 (en) | 2003-10-01 |
| AU2003200920A1 (en) | 2003-10-16 |
| ITMI20020681A1 (it) | 2003-09-29 |
| JP2003300878A (ja) | 2003-10-21 |
| CN1448128A (zh) | 2003-10-15 |
| JP4794115B2 (ja) | 2011-10-19 |
| NO20031448D0 (no) | 2003-03-28 |
| ITMI20020681A0 (it) | 2002-03-29 |
| NO20031448L (no) | 2003-09-30 |
| BR0300846A (pt) | 2004-08-17 |
| IL154762A0 (en) | 2003-10-31 |
| US20030185894A1 (en) | 2003-10-02 |
| ZA200302040B (en) | 2003-09-17 |
| US20060121119A1 (en) | 2006-06-08 |
| NO334407B1 (no) | 2014-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1259902C (zh) | 制造紫杉醇和白蛋白的纳米颗粒的方法 | |
| CN112245574B (zh) | 一种负载全细胞组分的靶向输送系统及其应用 | |
| CN1151114A (zh) | 在无菌条件下滤过性稳定微粒 | |
| EP3372226B1 (en) | Targeted hydrophobic anti-tumour drug nanoformulation and preparation method thereof | |
| CN1935121A (zh) | 改进的基于紫杉醇的抗肿瘤制剂 | |
| CN1245955C (zh) | 热保护微粒组合物及其最终蒸汽灭菌的方法 | |
| CN1507357A (zh) | 提高生物活性分子传递的方法和组合物 | |
| CN1190974A (zh) | 多糖凝胶组合物 | |
| CN1748705A (zh) | 包含孕酮的新的可注射制剂 | |
| CN1625414A (zh) | 药物组合物 | |
| CN1760227A (zh) | 具有疏水核心、亲水表面的纳米粒及其制备方法和应用 | |
| CN1604788A (zh) | 高浓度蛋白制剂及其制备方法 | |
| CN1686087A (zh) | 纳米磁性药物微球及其制备方法和应用 | |
| CN1760213A (zh) | 季铵化壳聚糖衍生物、其制备方法及含其的药物制剂 | |
| CN1795002A (zh) | 用于治疗癌症的基于岩石粉、更具体是白云石粉的药物 | |
| JP5116108B2 (ja) | 抗癌剤の伝達体用水溶性キトサンナノ粒子及びその製造方法 | |
| CN106214639B (zh) | 一种壳聚糖枝接西替利嗪纳米胶束的制备方法 | |
| CN1268346C (zh) | 生物多糖微胶囊及其制备方法和用途 | |
| CN110507631B (zh) | 一种制备白蛋白紫杉醇纳米粒的方法 | |
| CN1448132A (zh) | 改进的基于紫杉醇的抗肿瘤制剂 | |
| CN1802172A (zh) | 用于自身免疫性病症的治疗组合物 | |
| CN1843334A (zh) | 一种提高脂质体包封率的方法及其制剂 | |
| CN101040847A (zh) | 一种采用氢化蓖麻油生产的纳米药物制剂及其制备工艺 | |
| CN1209163C (zh) | 脑膜炎球菌疫苗及其制备方法 | |
| JP2001519797A (ja) | アレルゲン処方 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: ABRAXIS BIOSCIENCE INC Free format text: FORMER OWNER: AMERICA BIOLOGICAL SCIENCE CO., LTD. Effective date: 20070316 Owner name: AMERICA BIOLOGICAL SCIENCE CO., LTD. Free format text: FORMER OWNER: ACS DOBFAR SPA Effective date: 20070316 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20070316 Address after: American California Patentee after: American Bioscience Inc. Address before: Italy triy Arnold Patentee before: ACS Dobfar S.P.A. Effective date of registration: 20070316 Address after: American California Patentee after: ABRAXIS BIOSCIENCE, Inc. Address before: American California Patentee before: American Bioscience Inc. |
|
| ASS | Succession or assignment of patent right |
Owner name: ABRAXIS BIOSCIENCE CO., LTD. Free format text: FORMER OWNER: ABRAXIS BIOSCIENCE Effective date: 20090612 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20090612 Address after: American California Patentee after: ABRAXIS BIOSCIENCE, LLC Address before: American California Patentee before: ABRAXIS BIOSCIENCE, Inc. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20060621 |
|
| CX01 | Expiry of patent term |